Characterization of Non-Monotonic Relationships between Tumor Mutational Burden and Clinical Outcomes

被引:0
|
作者
Anaya, Jordan [1 ]
Kung, Julia [2 ]
Baras, Alexander S. [1 ,3 ,4 ]
机构
[1] Johns Hopkins Univ, Dept Pathol, Sch Med, CRB II 152,1550 Orleans St, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Biomed Informat & Data Sci, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
[4] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
来源
CANCER RESEARCH COMMUNICATIONS | 2024年 / 4卷 / 07期
关键词
CTLA-4; BLOCKADE; LANDSCAPE; MODELS;
D O I
10.1158/2767-9764.CRC-24-0061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Potential clinical biomarkers are often assessed with Cox regressions or their ability to differentiate two groups of patients based on a single cutoff. However, both of these approaches assume a monotonic relationship between the potential biomarker and survival. Tumor mutational burden (TMB) is currently being studied as a predictive biomarker for immunotherapy, and a single cutoff is often used to divide patients. In this study, we introduce a two-cutoff approach that allows splitting of patients when a non-monotonic relationship is present and explore the use of neural networks to model more complex relationships of TMB to outcome data. Using real-world data, we find that while in most cases the true relationship between TMB and survival appears monotonic, that is not always the case and researchers should be made aware of this possibility.Significance: When a non-monotonic relationship to survival is present it is not possible to divide patients by a single value of a predictor. Neural networks allow for complex transformations and can be used to correctly split patients when a non-monotonic relationship is present.
引用
收藏
页码:1667 / 1676
页数:10
相关论文
共 50 条
  • [41] Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis
    Meng, Guangxian
    Liu, Xiaowei
    Ma, Tian
    Lv, Desheng
    Sun, Ge
    PLOS ONE, 2022, 17 (02):
  • [42] Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer
    Sharpnack, Michael F.
    Cho, Ju Hwan
    Johnson, Travis S.
    Otterson, Gregory A.
    Shields, Peter G.
    Huang, Kun
    Carbone, David P.
    He, Kai
    LUNG CANCER, 2020, 146 : 36 - 41
  • [43] First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
    Ready, Neal
    Hellmann, Matthew D.
    Awad, Mark M.
    Otterson, Gregory A.
    Gutierrez, Martin
    Gainor, Justin F.
    Borghaei, Hossein
    Jolivet, Jacques
    Horn, Leora
    Mates, Mihaela
    Brahmer, Julie
    Rabinowitz, Ian
    Reddy, Pavan S.
    Chesney, Jason
    Orcutt, James
    Spigel, David R.
    Reck, Martin
    O'Byrne, Kenneth John
    Paz-Ares, Luis
    Hu, Wenhua
    Zerba, Kim
    Li, Xuemei
    Lestini, Brian
    Geese, William J.
    Szustakowski, Joseph D.
    Green, George
    Chang, Han
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (12) : 992 - +
  • [44] In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients
    Heeke, Simon
    Benzaquen, Jonathan
    Long-Mira, Elodie
    Audelan, Benoit
    Lespinet, Virginie
    Bordone, Olivier
    Lalvee, Salome
    Zahaf, Katia
    Poudenx, Michel
    Humbert, Olivier
    Montaudie, Henri
    Dugourd, Pierre-Michel
    Chassang, Madleen
    Passeron, Thierry
    Delingette, Herve
    Marquette, Charles-Hugo
    Hofman, Vronique
    Stenzinger, Albrecht
    Ilie, Marius
    Hofman, Paul
    CANCERS, 2019, 11 (09)
  • [45] Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
    Chae, Young Kwang
    Davis, Andrew A.
    Raparia, Kirtee
    Agte, Sarita
    Pan, Alan
    Mohindra, Nisha
    Villaflor, Victoria
    Giles, Francis
    CLINICAL LUNG CANCER, 2019, 20 (02) : 88 - +
  • [46] Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
    Alborelli, Ilaria
    Leonards, Katharina
    Rothschild, Sacha, I
    Leuenberger, Laura P.
    Prince, Spasenija Savic
    Mertz, Kirsten D.
    Poechtrager, Severin
    Buess, Martin
    Zippelius, Alfred
    Laubli, Heinz
    Haegele, Jasmin
    Tolnay, Markus
    Bubendorf, Lukas
    Quagliata, Luca
    Jermann, Philip
    JOURNAL OF PATHOLOGY, 2020, 250 (01): : 19 - 29
  • [47] Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
    Krieger, Tina
    Pearson, Isobel
    Bell, Judith
    Doherty, Jim
    Robbins, Paul
    DIAGNOSTIC PATHOLOGY, 2020, 15 (01)
  • [48] Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view
    Penault-Llorca, Frederique
    Radosevic-Robin, Nina
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 716 - 721
  • [49] PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy
    Li, Xiangmei
    He, Yalan
    Jiang, Ying
    Pan, Bingyue
    Wu, Jiashuo
    Zhao, Xilong
    Huang, Junling
    Wang, Qian
    Cheng, Liang
    Han, Junwei
    MOLECULAR THERAPY NUCLEIC ACIDS, 2023, 34
  • [50] Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non-small cell lung cancer
    Hu, Jing
    Shang, Yanhong
    Shi, Xiaoliang
    Zhang, Shuirong
    Shi, Junping
    Yao, Ming
    Wang, Aodi
    Shou, Tao
    Shi, Weiwei
    Wang, Kai
    Liu, Angen
    Pan, Xiaojie
    Wang, Yongjie
    ONCOLOGY REPORTS, 2020, 43 (06) : 2053 - 2061